Q3 2024 net income was $16 million, or $1.87 per diluted share, versus $24 million, or $2.71 per diluted share, in the prior ...

First patient dosed in Phase 2 clinical trial with NGC-Cap for metastatic breast cancer Positive data from preclinical studies support NGC-Iri’s ...